Methods | Using Medicaid state drug utilization data, we extracted fee-for-service and managed care reimbursement Figure) . From 2008-2014, Lantus accounted for approximately 80% of IU reimbursed for long-acting insulins, and insulin detemir accounted for the remaining 20%. Following the approval of new products, the market shares of Lantus and insulin detemir decreased to 42% and 14%, respectively. By Q1 2018, the market share of Basaglar reached 34% of all IU for long-acting insulins, or 44% of all IU for insulin glargine, 100 IU/mL (Table) . In Q1 2018, insulin glargine, 300 IU/mL, and insulin degludec each accounted for 5% of IU for long-acting insulins and insulin glargine-lixisenatide for 0.1%. Reimbursement rates for Lantus and insulin determir increased in parallel in 2006-2014 by an average of 13% annually but stabilized following new product entry. Without accounting for inflationary or supplemental rebates, Basaglar reimbursement rates have been 15% to 16% lower than those of Lantus since its entry. From Q4 2016 to Q2 2018, Basaglar entry resulted in savings of more than $70 million to Medicaid, or around 4.4% of expenditures on insulin glargine, 100 IU/mL.
Discussion | In the long-acting insulin market, new product entry was associated with a halt in increases in reimbursement levels for incumbent products. The first biosimilar insulin had a large uptake and was associated with modest reductions in insulin expenditures for Medicaid.
The present analysis has important limitations, including the unavailability of inflationary and supplemental rebate data and the potential effect on prices of external forces such as public pressure. Savings associated with Basaglar would be lower if supplemental rebates were larger for Lantus than for Basaglar. Additionally, it is not possible to determine whether the slowing of price increases for incumbent products was a result of Basaglar entry or due to the approval of branded competitors, which has not been shown to lower inflation in other therapeutic classes. 6 Nevertheless, these findings suggest that increased competition in the long-acting insulin market was associated with lower per-milliliter reimbursements in Medicaid, lending support to policies that expedite biosimilar approval and market entry. More savings should be expected once biosimilars are labeled as "interchangeable" and can be automatically substituted at the pharmacy, which is not currently the case for Basaglar. 5 innovator products are subject to a minimum statutory rebate of 23.1% of average manufacturer price. In analyses, the 23.1% rebate base was applied to the mean reimbursement amount per milliliter (100 international units [IU]) before rebates, which was the estimate available in the data. Because Basaglar was approved through a new drug application, it is treated as an innovator drug by Medicaid and therefore subject to the 23.1% rebate rate. These estimates do not account for additional rebates due to price increases above inflation or other supplemental rebates negotiated between manufacturers and Medicaid. c Number of milliliters (100 IU) reimbursed for Basaglar × (postrebate mean amount reimbursed for Lantus minus postrebate mean amount reimbursed for Basaglar). Results | Thirty-eight states identified pregnancy as a condition that influences either an incapacitated woman's advance directive or surrogate decision making (Figure) . No mention of medical decision making for incapacitated pregnant women.
US State Regulation of Decisions for Pregnant Women Without Decisional Capacity
Restrictions exist on decision making for pregnant patients, contingent on likelihood of fetal survival.
Restrictions exist on decision making for pregnant patients, regardless of likelihood of fetal survival. 
